Another potentially deadly outcome is persistent newborn pulmonary hypertension (PPHN), a condition that occurs when a newborn’s cardiac system fails to transition normally after birth. Numerous studies have shown that SSRI use late in pregnancy increases the risk of PPHN, some by as much as fivefold. In 2006, the FDA issued a public health advisory based on a study that found six times the risk of PPHN, but then five years later issued a retraction of sorts after subsequent studies did not find an elevated risk.
Even in the face of such muddy conclusions, to me the choice initially seemed obvious: Stop taking the meds and tough it out for the sake of the child. My reasoning was straightforward: There seemed to be a consensus, however foggy, that the drugs increased the risks of certain negative outcomes, if only very slightly.
Read the whole story: The Atlantic